HUP0303860A2 - Magas hatóanyag-tartalmú gyógyszertabletta - Google Patents

Magas hatóanyag-tartalmú gyógyszertabletta

Info

Publication number
HUP0303860A2
HUP0303860A2 HU0303860A HUP0303860A HUP0303860A2 HU P0303860 A2 HUP0303860 A2 HU P0303860A2 HU 0303860 A HU0303860 A HU 0303860A HU P0303860 A HUP0303860 A HU P0303860A HU P0303860 A2 HUP0303860 A2 HU P0303860A2
Authority
HU
Hungary
Prior art keywords
active ingredient
seed crystals
high active
pharmaceutical tablet
amount
Prior art date
Application number
HU0303860A
Other languages
English (en)
Inventor
Robert Paul Discordia
Soojin Kim
Sanjeev H. Kothari
Chiajen Lai
Omar Leopold Sprockel
Chenkou Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0303860A2 publication Critical patent/HUP0303860A2/hu
Publication of HUP0303860A3 publication Critical patent/HUP0303860A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

A találmány tárgya magas gyógyszerhatóanyag-tartalmú orális tabletta,amelyben a hatóanyag-komponens a készítménynek körülbelül 50% és 90%közötti részét képezi, és amely tartalmaz továbbá legalább egysegédanyagot, így mikrokristályos cellulózt, nátrium-keményítő-glikolátot, szilícium-dioxidot és magnézium-sztearátot. A magashatóanyagtartalmat a hatóanyag-komponens kristályosításánál akristálygócok képződésének megnövelésével, így megnövelt mennyiségűoltókristállyal, az oltókristályok részecskeméretének csökkentésével,illetve az oltókristályok mennyiségének és méretének megfelelőkombinálásával érik el. Ó
HU0303860A 2001-04-26 2002-04-23 A pharmaceutical tablet having a high active ingredient HUP0303860A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28668201P 2001-04-26 2001-04-26
US28687001P 2001-04-26 2001-04-26
PCT/US2002/012915 WO2002087548A1 (en) 2001-04-26 2002-04-23 A pharmaceutical tablet having a high api content

Publications (2)

Publication Number Publication Date
HUP0303860A2 true HUP0303860A2 (hu) 2004-03-29
HUP0303860A3 HUP0303860A3 (en) 2005-05-30

Family

ID=26964005

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0400377A HUP0400377A2 (en) 2001-04-26 2002-04-23 Control of compactability through crystallization
HU0303860A HUP0303860A3 (en) 2001-04-26 2002-04-23 A pharmaceutical tablet having a high active ingredient

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0400377A HUP0400377A2 (en) 2001-04-26 2002-04-23 Control of compactability through crystallization

Country Status (13)

Country Link
US (2) US20040175419A1 (hu)
EP (2) EP1390018A1 (hu)
JP (2) JP2004530679A (hu)
KR (1) KR20040036686A (hu)
CN (2) CN1523981A (hu)
BR (2) BR0209199A (hu)
CA (2) CA2445290A1 (hu)
CZ (2) CZ20032901A3 (hu)
HU (2) HUP0400377A2 (hu)
IL (2) IL158412A0 (hu)
MX (2) MXPA03009676A (hu)
PL (2) PL367262A1 (hu)
WO (2) WO2002087548A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
ATE228358T1 (de) 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
BRPI0514721A (pt) 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
KR101518427B1 (ko) 2006-06-15 2015-05-08 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
JP2013528214A (ja) 2010-06-07 2013-07-08 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物ｄ型の調製
CN102917694A (zh) * 2010-06-07 2013-02-06 泰立克公司 依泽替米贝的片剂制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
WO1993012768A1 (en) * 1991-12-30 1993-07-08 Fmc Corporation Microcrystalline cellulose spheronization composition
WO1997012902A1 (en) * 1995-10-05 1997-04-10 Darwin Discovery Limited Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation

Also Published As

Publication number Publication date
JP2004530679A (ja) 2004-10-07
BR0209155A (pt) 2004-10-05
KR20040036686A (ko) 2004-04-30
IL158412A0 (en) 2004-05-12
IL158235A0 (en) 2004-05-12
EP1390018A1 (en) 2004-02-25
CN1523981A (zh) 2004-08-25
HUP0400377A2 (en) 2007-09-28
US20040208924A1 (en) 2004-10-21
PL367262A1 (en) 2005-02-21
CA2445702A1 (en) 2002-11-07
PL373548A1 (en) 2005-09-05
CZ20032901A3 (en) 2004-07-14
WO2002088664A2 (en) 2002-11-07
WO2002088664A3 (en) 2003-08-21
HUP0303860A3 (en) 2005-05-30
MXPA03009676A (es) 2004-02-12
BR0209199A (pt) 2006-02-07
WO2002087548A1 (en) 2002-11-07
CZ20032902A3 (cs) 2004-01-14
MXPA03009689A (es) 2004-02-12
JP2005505501A (ja) 2005-02-24
EP1390011A2 (en) 2004-02-25
CN1520283A (zh) 2004-08-11
US20040175419A1 (en) 2004-09-09
CA2445290A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
HUP0303860A2 (hu) Magas hatóanyag-tartalmú gyógyszertabletta
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
GEP20084467B (en) Gamma crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it
HUP0402293A2 (hu) Fexofenadint tartalmazó szájban diszpergálódó tablettakészítmény, bevonatos granulátum és eljárás az előállítására
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GEP20084540B (en) 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CA2433585A1 (en) Pharmaceutical compositions containing donepezil hydrochloride
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
IL179718A0 (en) Pharmaceutical composition containing irbesartan
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
HK1076605A1 (en) Formulations
HUP0301325A2 (hu) Stabilizált, gyógyászatilag hatékony kompozíció és ezt tartalmazó gyógyszerkészítmény és eljárás a kompozíció előállítására
HUP0402492A2 (hu) 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
BR0212778A (pt) Composições de desintegração intra-oral organolepticamente aceitáveis
AR074739A1 (es) Comprimidos de capecitabina de disgregacion rapida
WO2021070200A3 (en) Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
MXPA03011317A (es) Comprimido masticable que comprende paracetamol.
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
ES2422729T3 (es) Sales de tiotropio, procedimiento para su preparación y formulaciones de medicamentos que las contienen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees